Get the Daily Brief
Latest Biotech News
Chinese team implants pig liver segment: graft supports patient 38 days
Surgeons in China transplanted a genetically modified pig liver segment into a patient with cancer and reported the graft supported metabolic function for 38 days before removal due to thrombotic...
Study suggests anti‑AAV antibodies aren’t absolute barrier to gene therapy
New research presented in Seville indicates that some patients who carry anti‑AAV antibodies—traditionally considered exclusionary for AAV‑based gene therapy—may still be eligible for treatment or...
Illumina consortium lures pharma: 250k genomes plus clinical data
Illumina’s Alliance for Genomic Discovery expanded its roster of industry partners, adding companies such as Alnylam and drawing interest from pharma teams seeking diverse genomes paired with...
Senate backs new Biosecure Act iteration: NDAA amendment tightens biotech ties
The US Senate passed a reworked Biosecure Act as an amendment to the National Defense Authorization Act, seeking to restrict certain federal contracting and funding relationships with companies...
Biopharma bets billions: in vivo CAR‑T deals surge and CAR‑iNK scale methods emerge
Large biopharma firms have spent billions in 2025 on companies developing in vivo CAR‑T approaches as first human data arrive, and separate teams reported methods for mass production of...
BMS pays $1.5B for Orbital: in‑vivo CAR‑T push
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion, acquiring an in‑vivo CAR‑T platform intended to reprogram immune cells inside patients without ex vivo manufacturing....
AstraZeneca agrees pricing pact — White House clinches pharma deal
AstraZeneca reached a drug‑pricing agreement with the White House, following earlier deals under the administration’s pricing initiative. Reports indicated the pact mirrors discounts other...
Novo shutters cell‑therapy unit; pivots after Akero buy
Novo Nordisk discontinued its cell therapy research unit and is laying off most staff in that division while shifting strategic resources toward metabolic and liver disease programs. The company...
FDA clears dordaviprone: first systemic option for H3(K27M) DMG
The U.S. Food and Drug Administration granted accelerated approval to dordaviprone for diffuse midline glioma (DMG) harboring the H3(K27M) mutation in patients aged one year and older with...
Sarepta readies gene‑therapy filing — potential first LGMD treatment
Sarepta Therapeutics reported data showing its experimental gene therapy increased expression of the missing gene in limb‑girdle muscular dystrophy type 2E (LGMD 2E) and said it plans to file for...
Partial pig liver transplant supports human patient — xenotransplant milestone
Chinese surgeons implanted a genetically modified pig liver segment into a patient with liver cancer; the graft functioned immediately and supported metabolic activity for 38 days before being...
Anti‑AAV antibodies challenged; durability concerns linger for gene therapy
New data presented in Seville suggest that some patients with preexisting anti‑AAV antibodies may still be eligible to receive gene therapies, challenging a common exclusion criterion and...
Illumina’s genomic alliance draws pharma partners — 250K genomes live
Illumina’s Alliance for Genomic Discovery (AGD) expanded its partner roster with Alnylam Pharmaceuticals joining the project that has sequenced more than 250,000 genomes from the Vanderbilt BioVU...
Regulatory shake‑up: FDA orphan‑drug office reassignment and Biosecure Act passes Senate
Regulatory turbulence intensified as the FDA reassigned the director of its Office of Orphan Products Development and the U.S. Senate passed a new iteration of the Biosecure Act as an amendment to...
Scalable CAR‑iNK manufacturing unveiled — NK cell therapies move toward scale
Researchers reported methods to mass‑produce CAR‑engineered induced natural killer (CAR‑iNK) cells, addressing a key bottleneck for NK‑cell immunotherapies: scalable, cost‑effective manufacturing....
BMS buys Orbital for $1.5B — in‑vivo CAR‑T push
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, buying an in‑vivo CAR‑T platform nearing clinical entry. The deal brings BMS an IV-administered program...
CAR‑iNK scale‑up... manufacturing enters the clinic
Groups reported methods for large‑scale manufacture of CAR‑engineered induced natural killer (CAR‑iNK) cells and surfaced next‑generation engineered T‑cell innovations, aiming to broaden...
Novo shutters cell therapy unit — pivots into big MASH buy
Novo Nordisk announced it is discontinuing its cell therapy R&D, laying off most of a ~250‑person unit and ending work on a Type‑1 diabetes cell program, while simultaneously striking a major...
AstraZeneca strikes pricing deal with White House — portfolio discounts
AstraZeneca reached a drug‑pricing agreement with the Trump administration, offering discounts across its portfolio in a move aligned with recent deals between the White House and other large...
Senate folds Biosecure Act into defense bill — new biotech constraints possible
The U.S. Senate added a new iteration of the Biosecure Act as an amendment to the National Defense Authorization Act, advancing language aimed at restricting federal funding or contracts with...